Protein degradation technology: a strategic paradigm shift in drug discovery
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Protein degradation technology: a strategic paradigm shift in drug discovery
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-09-06
DOI
10.1186/s13045-021-01146-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
- (2021) Green Ahn et al. Nature Chemical Biology
- PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
- (2021) Si-Min Qi et al. Frontiers in Pharmacology
- Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
- (2021) Jinyun Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Targeting selective autophagy by AUTAC degraders
- (2020) Daiki Takahashi et al. Autophagy
- Proteolysis‐targeting chimeras in drug development: A safety perspective
- (2020) Kevin Moreau et al. BRITISH JOURNAL OF PHARMACOLOGY
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- PROTACs: A novel strategy for cancer therapy
- (2020) Jing Liu et al. SEMINARS IN CANCER BIOLOGY
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment
- (2020) Steven Kregel et al. NEOPLASIA
- Development of CDK2 and CDK5 Dual Degrader TMX‐2172
- (2020) Nathanael Schiander Gray et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
- (2020) Daniel Peter Petrylak et al. JOURNAL OF CLINICAL ONCOLOGY
- Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
- (2020) Xin Li et al. Journal of Hematology & Oncology
- Monomeric targeted protein degraders
- (2020) Emily J. Hanan et al. JOURNAL OF MEDICINAL CHEMISTRY
- PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
- (2020) Sajid Khan et al. ONCOGENE
- Emerging New Concepts of Degrader Technologies
- (2020) Yu Ding et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Huntingtin-lowering strategies for Huntington’s disease
- (2020) Roger A. Barker et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
- (2020) Yonghan He et al. Journal of Hematology & Oncology
- Lysosome-targeting chimaeras for degradation of extracellular proteins
- (2020) Steven M. Banik et al. NATURE
- The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
- (2020) Mikołaj Słabicki et al. NATURE
- Manumycin polyketides act as molecular glues between UBR7 and P53
- (2020) Yosuke Isobe et al. Nature Chemical Biology
- Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study
- (2020) Feng Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- PROTAC: A promising technology for cancer treatment
- (2020) Xin Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo
- (2020) Mingming Wei et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Modeling the Degradation Effects of Autophagosome Tethering Compounds
- (2020) Hang Zhang et al. Neuroscience Bulletin
- Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
- (2020) Lu Lv et al. eLife
- A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo
- (2020) Lijie Zhao et al. NEOPLASIA
- Targeting the SARS-CoV-2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders
- (2020) Hafeez S. Haniff et al. ACS Central Science
- Discovery of heterocycle-containing α-naphthoflavone derivatives as water-soluble, highly potent and selective CYP1B1 inhibitors
- (2020) Jinyun Dong et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
- (2019) Taavi Neklesa et al. JOURNAL OF CLINICAL ONCOLOGY
- PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
- (2019) Christopher P. Tinworth et al. ACS Chemical Biology
- Rapid and Reversible Knockdown of Endogenously Tagged Endosomal Proteins via an Optimized HaloPROTAC Degrader
- (2019) Hannah Tovell et al. ACS Chemical Biology
- Acquired Resistance to BET-PROTACs(Proteolysis Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 ligase Complexes
- (2019) Lu Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Advances in targeted degradation of endogenous proteins
- (2019) Sascha Röth et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- ATTEC: a potential new approach to target proteinopathies
- (2019) Zhaoyang Li et al. Autophagy
- Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
- (2019) Zhaoyang Li et al. NATURE
- Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15
- (2019) Tyler B. Faust et al. Nature Chemical Biology
- Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs
- (2019) Hongying Gao et al. ACS Medicinal Chemistry Letters
- Pyroptosis: A new frontier in cancer
- (2019) Yuan Fang et al. BIOMEDICINE & PHARMACOTHERAPY
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of selective mono or dual PROTAC degrader probe of CDK isoforms
- (2019) Fei Zhou et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Synthesis and structure-activity relationship studies of α-naphthoflavone derivatives as CYP1B1 inhibitors
- (2019) Jinyun Dong et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands
- (2019) Xin Han et al. JOURNAL OF MEDICINAL CHEMISTRY
- AUTACs: Cargo-Specific Degraders Using Selective Autophagy
- (2019) Daiki Takahashi et al. MOLECULAR CELL
- Discovery of a first-in-class EZH2 selective degrader
- (2019) Anqi Ma et al. Nature Chemical Biology
- Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
- (2019) Mikihiko Naito et al. Frontiers in Chemistry
- Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders
- (2018) Mette Ishoey et al. ACS Chemical Biology
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
- (2018) Shanshan Gu et al. BIOESSAYS
- Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis
- (2018) Mikhail M. Savitski et al. CELL
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Recent Advances in the Development of Indazole-based Anticancer Agents
- (2018) Jinyun Dong et al. ChemMedChem
- Recent advances in CDK inhibitors for cancer therapy
- (2018) Amy B Heptinstall et al. Future Medicinal Chemistry
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
- (2018) Chong Qin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Small Molecule Targeted Recruitment of a Nuclease to RNA
- (2018) Matthew G. Costales et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Delineating the role of cooperativity in the design of potent PROTACs for BTK
- (2018) Adelajda Zorba et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemically induced proximity in biology and medicine
- (2018) Benjamin Z. Stanton et al. SCIENCE
- Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
- (2018) Robert Campbell et al. Journal of Clinical Medicine
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
- (2018) Sainan An et al. EBioMedicine
- Bromodomain Drug Discovery – the Past, the Present, and the Future
- (2018) Mehrosh Pervaiz et al. CHEMICAL RECORD
- Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
- (2018) Philipp M. Cromm et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Different Degradation Mechanisms of Inhibitor of Apoptosis Proteins (IAPs) by the Specific and Nongenetic IAP-Dependent Protein Eraser (SNIPER)
- (2018) Nobumichi Ohoka et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- The Diagnosis and Treatment of Prostate Cancer
- (2017) Mark S. Litwin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- In VivoKnockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
- (2017) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
- (2017) Calla M Olson et al. Nature Chemical Biology
- Targeted protein degradation by PROTACs
- (2017) Taavi K. Neklesa et al. PHARMACOLOGY & THERAPEUTICS
- Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics
- (2016) Najoua Lalaoui et al. CANCER CELL
- The ubiquitin–proteasome system and its potential application in hepatocellular carcinoma therapy
- (2016) Yan-Jie Chen et al. CANCER LETTERS
- Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling
- (2016) Rory T. Coffey et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview
- (2016) Peter M. Fischer MEDICINAL RESEARCH REVIEWS
- Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules
- (2016) Keiichiro Okuhira et al. MOLECULAR PHARMACOLOGY
- Induced protein degradation: an emerging drug discovery paradigm
- (2016) Ashton C. Lai et al. NATURE REVIEWS DRUG DISCOVERY
- Non-coding RNAs as drug targets
- (2016) Masayuki Matsui et al. NATURE REVIEWS DRUG DISCOVERY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
- (2015) Dennis L. Buckley et al. ACS Chemical Biology
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Targeting FAK scaffold functions inhibits human renal cell carcinoma growth
- (2015) Claire Béraud et al. INTERNATIONAL JOURNAL OF CANCER
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- FAK signaling in human cancer as a target for therapeutics
- (2015) Brian Y. Lee et al. PHARMACOLOGY & THERAPEUTICS
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- Ibrutinib in B-cell Lymphomas
- (2014) Kami Maddocks et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- A Near-IR Uncaging Strategy Based on Cyanine Photochemistry
- (2014) Alexander P. Gorka et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
- (2014) Irfan A. Asangani et al. NATURE
- Pharmacological targeting of the pseudokinase Her3
- (2014) Ting Xie et al. Nature Chemical Biology
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket
- (2014) Diane D'allard et al. PLoS One
- Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
- (2014) M. Ceribelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Endocytosis and Autophagy: Exploitation or Cooperation?
- (2014) S. A. Tooze et al. Cold Spring Harbor Perspectives in Biology
- Highlights of the Latest Advances in Research on CDK Inhibitors
- (2014) Jonas Cicenas et al. Cancers
- The human secretome atlas initiative: Implications in health and disease conditions
- (2013) Kristy J. Brown et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
- (2013) T Karantanos et al. ONCOGENE
- Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs
- (2013) J. Hines et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- Inhibitor of Apoptosis (IAP) Proteins-Modulators of Cell Death and Inflammation
- (2013) J. Silke et al. Cold Spring Harbor Perspectives in Biology
- Inhibitor Mediated Protein Degradation
- (2012) Marcus J.C. Long et al. CHEMISTRY & BIOLOGY
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- Autophagy: Renovation of Cells and Tissues
- (2011) Noboru Mizushima et al. CELL
- Silencing disease genes in the laboratory and the clinic
- (2011) Jonathan K Watts et al. JOURNAL OF PATHOLOGY
- Small-molecule hydrophobic tagging–induced degradation of HaloTag fusion proteins
- (2011) Taavi K Neklesa et al. Nature Chemical Biology
- Long non-coding RNAs in Huntington's disease neurodegeneration
- (2011) Rory Johnson NEUROBIOLOGY OF DISEASE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility
- (2010) Suyoun Chung et al. CANCER SCIENCE
- Strategies for discovering and derisking covalent, irreversible enzyme inhibitors
- (2010) Douglas S Johnson et al. Future Medicinal Chemistry
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Bruton’s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain
- (2009) Abdalla J. Mohamed et al. IMMUNOLOGICAL REVIEWS
- Autophagy: Basic Principles and Relevance to Disease
- (2008) Mondira Kundu et al. Annual Review of Pathology-Mechanisms of Disease
- Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression
- (2008) K. S.M. Smalley et al. CANCER RESEARCH
- Small Molecules Destabilize cIAP1 by Activating Auto-ubiquitylation
- (2008) Keiko Sekine et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More